Table 3. Multivariable regression for PFS and OS.
| PFS | OS | ||||
|---|---|---|---|---|---|
| Characteristics | HR (95% CI) | P | Characteristics | HR (95% CI) | P |
| PFS-pPET-RadScore | 120 (3.98–3625) | 0.006 | OS-pPET-RadScore | 16.1 (2.94–88.3) | 0.001 |
| BCLC staging system | BCLC staging system | ||||
| Stages A vs. B | 0.57 (0.07–4.65) | 0.60 | Stages A vs. B | 1.31 (0.28–6.18) | 0.73 |
| Stages A vs. C | 0.72 (0.33–1.59) | 0.42 | Stages A vs. C | 0.66 (0.31–1.42) | 0.29 |
| Serum AFP level | 0.98 (0.68–1.40) | 0.89 | Serum AFP level | 0.75 (0.45–1.26) | 0.28 |
| Size <5 vs. ≥5 cm | 0.87 (0.37–2.02) | 0.75 | Size <5 vs. ≥5 cm | 1.0 (0.45–2.26) | 0.99 |
| Stratified for BCLC staging system | |||||
| PFS pPET-RadScore | 92.2 (2.91–2916) | 0.01 | OS-pPET-RadScore | 24.8 (3.78–162) | 0.001 |
| Serum AFP level | 0.99 (0.69–1.40) | 0.93 | Serum AFP level | 0.76 (0.45–1.28) | 0.30 |
| Size < 5 vs. ≥ 5 cm | 0.86 (0.36–2.07) | 0.73 | Size < 5 vs. ≥ 5 cm | 0.89 (0.39–2.04) | 0.79 |
| Stratified for tumor size | |||||
| PFS-pPET-RadScore | 146 (3.97–5333) | 0.007 | OS-pPET-RadScore | 16.97 (2.90–99.3) | 0.002 |
| Serum AFP level | 0.96 (0.67–1.38) | 0.83 | Serum AFP level | 0.75 (0.45–1.26) | 0.28 |
| BCLC staging system | BCLC staging system | ||||
| Stages A vs. B | 0.64 (0.08–5.44) | 0.68 | Stages A vs. B | 1.0 (0.21–4.72) | 1.00 |
| Stages A vs. C | 0.76 (0.34–1.70) | 0.50 | Stages A vs. C | 0.57 (0.26–1.22) | 0.15 |
AFP, alpha-fetoprotein; HR, hazard ratio; CI; confidence interval; PFS, progression-free survival; OS, overall survival; BCLC, barcelona-clinic liver cancer.